dm+d
27948111000001101
Articles
Safety in lactation: Drugs for chronic bowel disorders
21 September 2020Additional information relating to breastfeeding To be used in conjunction with individual drug entries for specific information and guidance. Aminosalicylates for chronic bowel disorders Mesalazine…
Lactation Safety Information
-
Analogue of human glucagon-like peptide-2 (GLP-2) indicated for short bowel syndrome after surgery
No published evidence of safety
Low levels anticipated in milk due to the drug’s properties and likely to be degraded in infant’s GI tract
A potentially serious adverse effect has been found in animals, although not confirmed in human studies. This suggests teduglutide should be used with caution until more evidence is available
5 February 2017
New Medicines
Revestive (UK/EU), Gattex (US) Short bowel syndrome - pre-filled pen formulation
Information
Revestive (UK/EU), Gattex (US)
New formulation
Takeda
Takeda
Development and Regulatory status
Phase III Clinical Trials
Phase III Clinical Trials
Phase III Clinical Trials
Yes
Yes
Category
Analogue of human glucagon-like peptide-2 (GLP-2), a peptide secreted by L cells of the intestine which is known to increase intestinal and portal blood flow, inhibit gastric acid secretion, and decrease intestinal motility. Injected once daily.
The most common aetiology in adults is currently Crohns disease. Extrapolated figures of home parenteral nutrition centres and single-centre studies suggest an incidence of 2-5 per million [1].
Short bowel syndrome - pre-filled pen formulation
Subcutaneous injection
Further information
Yes